Premium
Resin Hemoperfusion in Hepatic Porphyrias
Author(s) -
Horák Jiří,
Martásek Pavel,
Kordač Václav,
Mertl Ladislav,
Jirsa Milan,
Tlusťáková Marie,
Houštková Hana
Publication year - 1985
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1985.tb04369.x
Subject(s) - hemoperfusion , porphyrin , clearance , porphyria , chemistry , porphyria cutanea tarda , urine , medicine , gastroenterology , anesthesia , surgery , urology , photochemistry , hemodialysis
In three types of hepatic porphyrias, 32 hemoperfusions over polyhema‐coated Amberlite XAD‐2 resin were performed. An attack of acute intermittent porphyria subsided after a 6‐h hemoperfusion. During the procedure, 13 L of plasma was completely cleared of porphyrins. In a child with variegate porphyria, the laboratory changes were slight and no clinical effect of hemoperfusion was seen. In a patient suffering from porphyria cutanea tarda resistant to standard therapy, 30 hemoperfusions were performed during a period of 10 months. The total plasma porphyrin concentration increased sharply following the start of the treatment, and preceding the fifth procedure it reached a peak of four times the initial value. Since then, the plasma porphyrin level decreased, eventually to one‐half the starting value. The mean drop in porphyrin level during each perfusion was 22%. Similar changes were observed in the amount of porphyrins excreted into the urine, which, following an early rise, decreased to 25% of the initial value. However, the patient's skin vulnerability improved only slightly. There were no untoward effects of the treatment.